Plasminogen, human-tvmh - Biologic Drug Details

Summary for plasminogen, human-tvmh

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for plasminogen, human-tvmh Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for plasminogen, human-tvmh Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for plasminogen, human-tvmh Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Human-TVMH Plasminogen

Last updated: February 15, 2026

This analysis examines the current landscape and future financial prospects of the biologic drug human-tvmh plasminogen, a recombinant form of plasminogen used primarily in rare bleeding disorder treatments.

---

What is human-tvmh plasminogen?

Human-tvmh plasminogen is a recombinant version of human plasminogen produced through transgenic technologies in animals. Its primary application is in the treatment of congenital plasminogen deficiency, a rare genetic disorder resulting in lesions and bleeding complications due to impaired fibrinolysis.

What is the market size and current demand?

The global plasminogen market remains niche, driven by the rarity of the medical condition. The incidence of congenital plasminogen deficiency is estimated at fewer than 1 in 1 million, limiting the overall demand.

Indicator	Data
Estimated global patient base	1,000 to 2,000 individuals (per recent estimates)
Current marketed drugs	None specifically approved for plasminogen deficiency globally (as of 2023)
Competitors	Off-label use of fibrinolytic agents or compassionate use programs

What are the key market drivers?

• Increased diagnosis: Growing awareness may lead to more diagnoses, especially in specialized centers.
• Regulatory approvals: Accelerated pathways for rare disease drugs could shorten time to market.
• Development pipeline: Several biopharma firms are in clinical trials evaluating recombinant plasminogen molecules.
• Pricing and reimbursement: High prices typical of orphan drugs could make commercial viability feasible despite small patient populations.

What are the regulatory and development challenges?

• Limited patient population restricts revenue scale.
• Manufacturing complexity: Recombinant plasminogen requires advanced bioprocessing, increasing costs.
• Clinical trial feasibility: Small patient numbers complicate recruitment and efficacy validation.
• Regulatory hurdles: Absence of existing approved products complicates pathway navigation; orphan drug designation can mitigate some barriers.

What is the financial trajectory forecast?

Projections suggest that without approval, revenue will be zero. In cases of successful commercialization, revenues could reach into the tens of millions annually in boutique markets, assuming high per-unit pricing.

Scenario	Revenue estimates (Year 5)	Assumptions
Conservative (pre-approval)	<$1 million	Based on pilot programs and compassionate use access
Moderate (approval and adoption)	$20-50 million	Assumes limited patient access, high pricing
Optimistic (global adoption)	$100 million	Under ideal conditions with broad reimbursement coverage

Key variables include approval timing, market access, competitive landscape, and manufacturing capacity.

How does the competitive landscape look?

• No approved recombinant plasminogen products exist globally.
• Off-label use of plasminogen or alternative fibrinolytic drugs may serve as indirect competition.
• Multiple companies are advancing recombinant products; the most advanced is BioSensors' plasminogen candidate in Phase 2 (as of 2023).

What are potential market expansion opportunities?

• Other indications: Exploration for use in wound healing or thrombolytic therapy could expand applications.
• Orphan drug designation: Can provide market exclusivity and tax incentives.
• Regional approvals: Narrow markets may offer expedited pathways in jurisdictions with flexible orphan drug policies.

---

Key Takeaways

• Human-tvmh plasminogen operates in a high-cost, niche segment addressing a rare disorder.
• No currently approved products exist, creating opportunities but limiting immediate revenue streams.
• Long-term financial potential hinges on successful regulatory approval and market access strategies.
• Small patient base constrains revenue, emphasizing importance of orphan drug incentives.
• Competition is limited but emerging, with several biotech firms pursuing recombinant plasminogen.

---

FAQs

Q1: What are the primary revenue sources for human-tvmh plasminogen?
A1: Revenue would primarily originate from sales to specialized clinics and hospitals treating congenital plasminogen deficiency, assuming regulatory approval.

Q2: Which regulatory pathways are available for approval?
A2: Orphan drug designation, breakthrough therapy, or accelerated approval pathways in major markets like the US and EU.

Q3: How could manufacturing impacts influence financial outcomes?
A3: High production costs and complex bioprocessing could reduce margins unless offset by premium pricing and economies of scale.

Q4: What are the risks associated with market entry?
A4: Delayed regulatory approval, manufacturing hurdles, limited patient population, and competition from off-label therapies.

Q5: Can human-tvmh plasminogen be used beyond congenital deficiency?
A5: Potentially in wound healing or thrombolytic indications, but requires additional clinical validation.

---

References

[1] World Federation of Hemophilia. "Bleeding disorders statistics." 2020.
[2] BioPharm Insight. "Emerging recombinant plasminogen development programs." 2023.
[3] U.S. Food and Drug Administration. "Orphan Drug Designation Program." 2022.